Side-by-side comparison of AI visibility scores, market position, and capabilities
Metabolic health program combining continuous glucose monitoring with nutrition coaching; prediabetes prevention for employer wellness programs competing with Virta Health and Omada.
Gradia Health is a digital health company providing personalized metabolic health programs that combine continuous glucose monitoring (CGM), one-on-one nutrition coaching, and lifestyle interventions to prevent and reverse chronic metabolic conditions including prediabetes, insulin resistance, and metabolic syndrome. Founded in 2020 in San Francisco, Gradia raised $4.33-6.83 million in funding and generated $1.1 million in revenue in 2024, serving patients through both employer-sponsored health benefits and direct-to-consumer program enrollment.\n\nGradia's program pairs participants with a continuous glucose monitor that provides real-time blood sugar data, then connects them with registered dietitians and health coaches who use that data to personalize meal plans and behavioral interventions. The CGM data reveals how individual participants' blood sugar responds to specific foods, exercise, sleep, and stress — enabling precision nutrition recommendations that go beyond generic dietary guidelines. Programs typically run 3-6 months and focus on sustainable lifestyle changes supported by regular coach check-ins.\n\nIn 2025, Gradia operates in the rapidly growing metabolic health digital platform market alongside Levels Health (CGM for optimization), Virta Health (type 2 diabetes reversal), Noom (behavioral weight loss), and Omada Health (preventive health coaching) for the employer wellness and direct-to-consumer metabolic health programs. The employer-sponsored wellness market is particularly active as self-insured employers recognize that preventing metabolic disease is significantly cheaper than treating its downstream consequences (heart disease, type 2 diabetes, kidney disease). Gradia's 2025 strategy focuses on growing employer contracts with self-insured mid-market companies, deepening the CGM-based coaching methodology with AI-powered insights, and expanding the clinical evidence base for the program's outcomes.
Rare disease biotech developing polytherapy approach for Rett Syndrome (1 in 10,000 girls); founder-developed protocol validated through personal patient experience competing with Acadia Pharmaceuticals Daybue in Rett market.
Uncommon Therapeutics is a biotech company founded by Noah Auerhahn — directly inspired by his daughter's diagnosis with Rett Syndrome, a severe genetic neurological disease affecting approximately 1 in 10,000 girls — applying a polytherapy approach (combining multiple therapeutic agents targeting different disease mechanisms simultaneously) to develop treatments for serious neurological and rare diseases. After improving his daughter's quality of life through a personally developed polytherapy protocol, Auerhahn founded Uncommon Therapeutics to translate these insights into pharmaceutical products for the broader Rett Syndrome patient community.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.